VALDIR SABBAGA AMATO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
LIM/46 - Laboratório de Parasitologia Médica, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/46 - Laboratório de Parasitologia Médica, Hospital das Clínicas, Faculdade de Medicina - Líder
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Tegumentary leishmaniasis mimicking visceralization in a cirrhotic patient: atypical cutaneous lesions and local immunological features(2020) VERNAL, Sebastian; CASAL, Yuri; VIEIRA, Lucas T.; AMATO, Valdir S.; DUARTE, Maria Irma S.; NASTRI, Ana Catharina S. S.Tegumentary leislunaniasis (TL) diagnosis is challenging due to the lack of a gold standard diagnostic tool. The diagnosis is significantly harder in regions where visceral leishmaniasis (VL) is also prevalent since immunological tests may present cross-reactivity. A cirrhotic patient from an endemic Brazilian region for TL and VL presented with atypical cutaneous lesions, a usual clinico-laboratory feature of VL (including a positive rk39 test result), but he was diagnosed with TL histopathologically; VL was ruled out by necropsy. Physicians working in co-prevalent areas should be aware of atypical features, unusual clinical course, and unexpected laboratory findings of leishmaniasis.
- F-18-FDG PET/CT in the Follow-Up of Mucosal Leishmaniasis(2018) CAMARGO, Raphael A.; CAMARGO, Lazaro M.; SAPIENZA, Marcelo T.; BUCHPIGUEL, Carlos A.; AMATO, Valdir S.; TUON, Felipe Francisco
- Short Report: Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?(2011) AMATO, Valdir S.; TUON, Felipe F.; CAMARGO, Raphael A.; SOUZA, Regina M.; SANTOS, Carolina R.; NICODEMO, Antonio C.Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).
- Influence of chitosan/clay in drug delivery of glucantime from PVP membranes(2014) OLIVEIRA, Maria J. A.; SILVA, Estefania O.; BRAZ, Lucia M. A.; MAIA, Regina; AMATO, Valdir S.; LUGAO, Ademar B.; PARRA, Duclerc F.Polymeric hydrogels are receiving much attention in the past few years, as intelligent materials due to their properties for biomaterials. In this work, hydrogels of poly(N-2-vinil-pirrolidone) (PVP) containing chitosan and clay nanoparticles were obtained and characterized for glucantime drug delivery. The matrixes were crosslinked by gamma irradiation process with doses of 25 kGy. Hydrogels morphologies were observed by a Scanning Electron Microscope (SEM). The structural properties of the network were determined by gel fraction and swelling kinetic at 22 degrees C to study the capacity of water retention and, finally, drug delivery tests were performed ""in vitro"". The system showed higher gel fraction for the matrix with 1.0% of clay. In this case, besides the interactions of clay ions with PVP, there were interactions of chitosan with PVP. The results of glucantime delivery at the chitosan/PVP and clay system were discussed.
- Disease Severity Prediction by Spirometry in Adults with Visceral Leishmaniasis from Minas Gerais, Brazil(2017) MAIA, Isabel A.; BEZERRA, Frank S.; ALBUQUERQUE, Andre Luis Pereira de; ANDRADE JR., Heitor F.; NICODEMO, Antonio C.; AMATO, Valdir S.Visceral leishmaniasis (VL) is associated with interstitial pneumonitis according to histology and radiology reports. However, studies to address the functional impact on respiratory function in patients are lacking. We assessed pulmonary function using noninvasive spirometry in a cross-sectional study of hospitalized adult VL patients from Minas Gerais, Brazil, without unrelated lung conditions or acute infections. Lung conditions were graded as normal, restrictive, obstructive, or mixed patterns, according to Brazilian consensus standards for spirometry. To control for regional patterns of lung function, we compared spirometry of patients with regional paired controls. Spirometry detected abnormal lung function in most VL patients (70%, 14/20), usually showing a restrictive pattern, in contrast to regional controls and the standards for normal tests. Alterations in spirometry measurements correlated with hypoalbuminemia, the only laboratory value indicative of severity of parasitic disease. Abnormalities did not correlate with unrelated factors such as smoking or occupation. Clinical data including pulmonary symptoms and duration of therapy were also unrelated to abnormal spirometry findings. We conclude that the severity of VL is correlated with a restrictive pattern of lung function according to spirometry, suggesting that there may be interstitial lung involvement in VL. Further studies should address whether spirometry could serve as an index of disease severity in the management of VL.
- A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil(2023) LYRA, Marcelo R.; OLIVEIRA, Liliane F. A.; SCHUBACH, Armando O.; SAMPAIO, Raimunda N. R.; RODRIGUES, Bruna C.; HUEB, Marcia; COTA, Glaucia; SILVA, Rosiana E.; FRANCESCONI, Fabio; POMPILIO, Mauricio A.; FRANCA, Adriana O.; AMATO, Valdir S.; SOUZA, Regina M.; OLIVEIRA, Raquel V. C.; VALETE, Claudia M.; PIMENTEL, Maria I. F.Background Meglumine antimoniate (MA) remains the main treatment for cutaneous leishmaniasis (CL). Uncontrolled studies suggest that intralesional MA (IL-MA) may be noninferior and safer than systemic MA (S-MA). Methods Multicenter, randomized, controlled, open-label, phase 3 clinical trial to evaluate the efficacy and toxicity of IL-MA in 3 infiltrations at 14-day intervals compared with S-MA (10-20 mg Sb5+/kg/day, 20 days) for CL, with noninferiority margin of 20%. Primary and secondary outcomes were definitive cure at day 180 and epithelialization rate at day 90 of treatment, respectively. A 2-year follow-up was performed to assess relapses and emergence of mucosal lesions. Adverse events (AEs) were monitored according to the Division of AIDS AE grading system. Results We evaluated 135 patients. The cure rates (95% confidence interval) for IL-MA and S-MA treatment were, respectively, 82.8% (70.5-91.4) and 67.8% (53.3-78.3) per protocol (PP) and 70.6% (58.3-81.0) and 59.7% (47.0-71.5) per intention to treat (ITT). The epithelialization rates of the IL-MA and S-MA treatment were, respectively, 79.3% (66.6-88 + 8) and 71.2% (57.9-82.2) PP and 69.1% (55.2-78.5) and 64.2% (50.0-74.2) ITT. AEs in the IL-MA and S-MA groups were, respectively, clinical, 45.6% and 80.6%; laboratory, 26.5% and 73.1%; and electrocardiogram, 8.8% and 25.4%. Ten participants in the S-MA group and 1 in the IL-MA group were discontinued due to severe or persistent AEs. Conclusions IL-MA provides a similar cure rate and results in less toxicity compared with S-MA and may be used as first-line therapy for CL patients. This multicenter, randomized, controlled, open-label, phase 3 clinical trial, we evaluated the efficacy and toxicity of intralesional infiltration meglumine antimoniate (IL-MA) compared with systemic MA (S-MA) for cutaneous leishmaniasis (CL). IL-MA provides similar cure rate and results in less toxicity compared with S-MA. Clinical Trials Registration. REBEC: RBR-6mk5n4.